Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW, Warren RB, Zhong Y, Zhuo J, Cichewicz A, Kadambi A, Junqueira D, Westley T, Kisa R, Daamen C, Augustin M. Armstrong AW, et al. Among authors: kisa r. Dermatol Ther (Heidelb). 2023 Nov;13(11):2839-2857. doi: 10.1007/s13555-023-01034-7. Epub 2023 Oct 6. Dermatol Ther (Heidelb). 2023. PMID: 37801281 Free PMC article.
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Thaçi D, et al. Among authors: kisa rm. Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. Dermatol Ther (Heidelb). 2022. PMID: 35025062 Free PMC article.
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).
Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, Singh J, Spuls P, Thomas KS, Admani S, Aoki V, Ardeleanu M, Barbarot S, Berger T, Bergman JN, Block J, Borok N, Burton T, Chamlin SL, Deckert S, DeKlotz CC, Graff LB, Hanifin JM, Hebert AA, Humphreys R, Katoh N, Kisa RM, Margolis DJ, Merhand S, Minnillo R, Mizutani H, Nankervis H, Ohya Y, Rodgers P, Schram ME, Stalder JF, Svensson A, Takaoka R, Teper A, Tom WL, von Kobyletzki L, Weisshaar E, Zelt S, Williams HC. Chalmers JR, et al. Among authors: kisa rm. Br J Dermatol. 2014 Dec;171(6):1318-25. doi: 10.1111/bjd.13237. Epub 2014 Nov 14. Br J Dermatol. 2014. PMID: 24980543 Free PMC article.
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.
Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, Westley T, Kisa RM, Huang YH, Gao XH, Jo SJ, Armstrong AW. Tsai TF, et al. Among authors: kisa rm. J Dermatol. 2024 Nov 11. doi: 10.1111/1346-8138.17448. Online ahead of print. J Dermatol. 2024. PMID: 39526612
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial.
Zhang J, Ding Y, Wang P, Li L, Pan W, Lu Y, Cheng H, Jiang X, Ho JC, Guo S, Liu L, Chatterjee A, Kisa RM, Banerjee S. Zhang J, et al. Among authors: kisa rm. Br J Dermatol. 2024 Oct 22:ljae406. doi: 10.1093/bjd/ljae406. Online ahead of print. Br J Dermatol. 2024. PMID: 39437312
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
Armstrong AW, Augustin M, Beaumont JL, Pham TP, Hudgens S, Gordon KB, Zhuo J, Becker B, Zhong Y, Kisa RM, Banerjee S, Papp KA. Armstrong AW, et al. Among authors: kisa rm. Dermatol Ther (Heidelb). 2024 Aug;14(8):2235-2248. doi: 10.1007/s13555-024-01224-x. Epub 2024 Jul 30. Dermatol Ther (Heidelb). 2024. PMID: 39080153 Free PMC article.
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.
Korman NJ, Warren RB, Bagel J, Armstrong AW, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa RM, Banerjee S, Blauvelt A. Korman NJ, et al. Among authors: kisa rm. J Dermatolog Treat. 2024 Dec;35(1):2371045. doi: 10.1080/09546634.2024.2371045. Epub 2024 Jun 30. J Dermatolog Treat. 2024. PMID: 38945549 Free article. Clinical Trial.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Strober B, et al. Among authors: kisa rm. J Eur Acad Dermatol Venereol. 2024 Aug;38(8):1543-1554. doi: 10.1111/jdv.19925. Epub 2024 Mar 7. J Eur Acad Dermatol Venereol. 2024. PMID: 38451052 Clinical Trial.
23 results